|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,408 GBX | +0.57% |
|
-7.00% | +18.82% |
| Apr. 25 | Transcript : Indivior PLC, Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | London-listed Indivior Confirms Plan for Primary Listing in US | MT |
Addex Therapeutics Ltd announced that it has received CHF 2,700,000 in a round of funding on August 3, 2023. The transaction included participation from returning investor Indivior PLC.
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 1,408 GBX | +0.57% | -7.00% | 2.38B | ||
| 0.1155 CHF | +0.43% | -23.26% | 16.19M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +18.82% | 2.38B | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| -0.50% | 1.64B |
INDIVIOR PLC 
